WebTalaris Therapeutics. Erin Stevens. Email. Direct. Cell Processing Associate. United States, Kentucky, Louisville. Talaris Therapeutics. Install ZoomInfo Community App. To get companies and prospects information just run the installation wizard and get the ZoomInfo Community Edition. 1. Install Web6 Jan 2024 · Press Releases. Year. March 27, 2024. Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference. March 6, 2024. Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa.
Talaris Therapeutics Company Profile: Stock Performance
WebUp to 6 weeks of paid leave for new parents. Annual performance-based bonus. Employee referral bonus program. Paid leave for organ and bone marrow donation. 401k plan with company match. Location flexibility with a team that spans the country. Internal recognition program honoring employee contributions. Web12 Apr 2024 · 3 Wall Street analysts have issued 12-month target prices for Talaris Therapeutics' stock. Their TALS share price forecasts range from $3.00 to $23.00. On average, they expect the company's share price to reach $13.00 in the next year. This suggests a possible upside of 630.3% from the stock's current price. sia song with kendrick lamar
Talaris Therapeutics Company Profile: Stock Performance
WebDescription. Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Web10 Nov 2024 · Talaris Therapeutics, Inc. is developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and … Investment Date Original Shares Original Value Current Shares Current Value % … Historic Price Lookup - Investors Talaris Therapeutics, Inc. Debjit Chattopadhyay, Ph.D - Investors Talaris Therapeutics, Inc. Mani Foroohar, M.D - Investors Talaris Therapeutics, Inc. Vikram Purohit - Investors Talaris Therapeutics, Inc. Talaris is a mission-driven company working to harness the power of immune … Talaris Therapeutics Provides Clinical Update on FREEDOM-1 and Presents … BOSTON and LOUISVILLE Ky., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Talaris … WebTalaris Therapeutics is funded by 14 investors. Viking Global Investors and Eventide are the most recent investors. Funding Rounds Number of Funding Rounds 2 Total Funding Amount $215M Talaris Therapeutics has raised a total of $215M in funding over 2 rounds. Their latest funding was raised on Oct 6, 2024 from a Series B round. sia sports ground exemption